Evaxion Biotech awarded Eurostars grant to develop a therapeutic antibody against drug-resistant Klebsiella pneumoniae.

Evaxion is leading a Pan-European Consortium consisting of five partners, including Evaxion Biotech, MAB Discovery, Karolinska Institute, Pepscan Therapeutics and Preclin Biosystems. As part of a project estimated to cost €3 Million, the Consortium has received a €1,6 Million Eurostars Grant to support “Selection and development of a therapeutic antibody against drug-resistant Klebsiella Pneumoniae.” Commencing in January 2018, the Corsortium will collaborate to combine unique knowledge and expertise in drug development to develop and perform the preclinical validation of an innovative therapeutic strategy against antibiotic-resistant Klebsiella pneumoniae infections, and aim to launch within 3 years..

Recent News